She will leave Lundbeck no later than Dec 31, 2023.

"I want to personally thank Elise for her strong dedication and hard work with both P&O as well as Communication in Lundbeck. She has really made a difference for us across both departments during the last 4 years, and both functions now have a strong foundation to build on, when it comes to strengthening the communication of Lundbeck's role in restoring brain health. We wish Elise the very best of all in her future endeavors," says Deborah Dunsire, CEO at Lundbeck.

The search for a successor has been initiated and a new EVP and Chief People officer at Lundbeck will be announced in due course.
 

Contacts

Thomas Mikkel Mortensen Palle Holm Olesen
Media Relations Lead, Corp. Communication Vice President, Investor Relations
THMR@lundbeck.com PALO@lundbeck.com
+45 30 83 30 24 +45 30 83 24 26

About H. Lundbeck A/S
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research.

We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. 

For additional information, we encourage you to visit our corporate site www.lundbeck.com (https://www.lundbeck.com/global) and connect with us via LinkedIn (https://www.linkedin.com/company/lundbeck/).